Ossium Health Announces FDA Clearance of its Investigational New Drug Application for Treatment of Perianal Fistulizing Crohn’s Disease

Ossium Health, Inc. announced that the US FDA has accepted its Investigational New Drug application for OSSM-001, an MSC product, for the treatment of refractory perianal fistulas in patients with Crohn’s disease.